{"analyses":[{"ciLowerLimit":"0.724","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.039","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1158","paramType":"Hazard Ratio (HR)","paramValue":"0.867","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.32","upperLimit":"7.26","value":"5.55"},{"groupId":"OG001","lowerLimit":"4.60","upperLimit":"5.62","value":"5.52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"331"},{"groupId":"OG001","value":"330"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the date of first documented progression of disease or death from any cause in the absence of disease progression using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, as assessed by investigator. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants known to be alive and without disease progression were censored at the date of their last adequate tumor assessment per RECIST 1.1 criteria, or date of randomization (whichever is later).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Imlunestrant 400 milligrams (mg) orally once daily on days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation were met.","id":"OG000","title":"Arm A: Imlunestrant"},{"description":"Participants received the investigator's choice of endocrine therapy, either exemestane 25 mg administered orally once daily on days 1 to 28 of a 28-day cycle, or Fulvestrant 500 mg intramuscularly on days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond, until disease progression or a criterion for discontinuation was met.","id":"OG001","title":"Arm B: Investigator's Choice of Endocrine Therapy"}],"paramType":"MEDIAN","populationDescription":"All participants who were randomly assigned to either arm A or arm B (including censored). Number of participants censored in \"Arm A=94,\" \"Arm B=77.\"","reportingStatus":"POSTED","timeFrame":"Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)","title":"Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)","type":"PRIMARY","unitOfMeasure":"Months"}